石药达成潜在金额超12亿美元交易,中国药企“青苗”为何持续受青睐

第一财经
19 Feb

2月19日早间,石药集团公告,石药巨石已与Radiance Biopharma就集团的重组抗人类受体酪氨酸激酶样孤儿受体1(ROR1)抗体偶联药物(ADC)SYS6005在美国、欧盟等国家地区的开发及商业化订立独家授权协议。这也是国内生物药物最新达成的一项海外授权交易,总价值有望超过12亿美元。根据该协议条款,石药巨石将收取1500万美元的首付款,并有权收取最高1.5亿美元的潜在开发及监管里程碑...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10